Table 3.

Patients characteristics of 7 included studies

Study, year	Design	Age (years) T/C	Male T/C	HF T/C	HTN T/C	CAD T/C	HbA1c (%) T/C	β-blocker T/C	CCB T/C	ACEI/ARB T/C	Statin T/C	Insulin T/C
PROactive, 2005 [12]	RCT	61.9/61.6	67%/66%	NA	75%/76%	48%/48%	7.8/7.9	55%/54%	34%/37%	70%/70%	43%/43%	33.2%/34%
Anglade, 2007 [13]	Nested case control study of patients from the AFIST I, II and III trials	65.8/67.2	72.5%/71.5%	15.0%/18.8%	90.0%/75.7%	NA	NA	75.0%/75.0%	12.5%/21.5%	75.0%/56.9%	77.5%/61.8%	NA
RECORD, 2009 [14]	RCT	58.4/58.5	51.4%/51.7%	0.5%/0.4%	NA	NA	7.9/7.9	22.6%/20.9%	19.1%/21.6%	43.1%/42.1%	18%/19.2%	NA
Gu, 2011	Prospective cohort study	59.6/58.7	52.9%/45.5%	0/0	62.7%/72.7%	5.9%/5.1%	6.2/6.4	35.3%/37.4%	35.3%/28.3%	56.9%/45.5%	13.7%/12.1%	3.9%/2.0%
Chao, 2012 [16]	Nested case control study of patients from NHIRD	53.7/54.1	52.9%/53.6%	4.1%/4.7%	38.1%/44.5%	16.9%/18.4%	NA	45.5%/46.4%	NA	68.6%/68.3%	59%/57.4%	0/0
Liu, 2014 [17]	RCT	60.70/62.25	74.3%/ 65.8%	0/0	28.6%/30.3%	28.6%/30.3%	6.41/6.19	41.4%/38.2%	20%/17.1%	NA	31.4%/34.2%	NA
Pallisgaard, 2016 [18]	Prospective cohort study	59.59/62.40	56.7%/ 58.1%	2.3%/4.9%	50.2%/48.4%	NA	NA	31.5%/31.5%	NA	58.8%/55.9%	58.0%/53.0%	NA

Abbreviations: RCT randomized controlled trial, HF heart failure, HTN hypertension, CAD Coronary arterial disease, HbA1c haemoglobin A1c, CCB calcium channel blocker, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, T/C thiazolidinediones group/control group, NA not applicable